Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Early-life viral infection generates pathological tissue-resident memory cells that contribute to asthma-like disease
Emma E. Brown, Jie Lan, Olivia B. Parks, Li Fan, Dequan Lou, Alysia McCray, Lisa Mathews, Alexander J. Wardropper, Anna Shull, Michelle L. Manni, Heth R. Turnquist, Kong Chen, Taylor Eddens
Emma E. Brown, Jie Lan, Olivia B. Parks, Li Fan, Dequan Lou, Alysia McCray, Lisa Mathews, Alexander J. Wardropper, Anna Shull, Michelle L. Manni, Heth R. Turnquist, Kong Chen, Taylor Eddens
View: Text | PDF
Research Article Immunology Infectious disease Pulmonology

Early-life viral infection generates pathological tissue-resident memory cells that contribute to asthma-like disease

  • Text
  • PDF
Abstract

Viral lower respiratory tract infections are common early in life and are associated with long-term development of asthma, a chronic condition defined by reversible airflow obstruction secondary to inflammation. Understanding the immunological mechanism connecting these two pathologies observed early in life becomes imperative to guide therapeutic measures. To investigate this connection, neonatal (days 4–6) or adult mice were infected with human metapneumovirus (HMPV) followed by a secondary HMPV infection 6 weeks later. Mice initially infected as neonates demonstrated increased mucus production, eosinophil recruitment, airway hyperresponsiveness, and Th2 T cell differentiation after rechallenge compared with adult mice rechallenged with HMPV. Neonatal HMPV infection led to formation of Th2 clonally expanded tissue-resident memory (TRM) T cells that were absent after adult HMPV. FTY720-mediated disruption of lymphocyte circulation demonstrated that TRMs contributed to pathology. Local depletion of lung CD4+ T cells and JAK2 inhibition mitigated pathology. These findings suggest TRMs uniquely generated after early-life viral infection can contribute to Th2-driven asthma pathology.

Authors

Emma E. Brown, Jie Lan, Olivia B. Parks, Li Fan, Dequan Lou, Alysia McCray, Lisa Mathews, Alexander J. Wardropper, Anna Shull, Michelle L. Manni, Heth R. Turnquist, Kong Chen, Taylor Eddens

×

Figure 6

Local depletion of CD4+ T cells partially mitigates asthma pathology.

Options: View larger image (or click on image) Download as PowerPoint
Local depletion of CD4+ T cells partially mitigates asthma pathology.
Mi...
Mice were treated with low-dose anti-CD4 antibody (100 μg; o.p.), high-dose anti-CD4 antibody (i.p.), or isotype control (o.p.) 1 day prior to HMPV reinfection. (A) Administration of o.p. and i.p. anti-CD4 antibody significantly reduced lung CD4+ T cells with an activated phenotype in the lung at day 3 after rechallenge. (B) Quantification of GATA3+CD4+ T cells after anti-CD4 treatment. (C) IL-4 production at day 3 after rechallenge was significantly reduced in mice treated with o.p. or i.p. anti-CD4. (D) Recovery of CD4+ T cells by day 7 after rechallenge was observed in o.p. but not i.p. anti-CD4–treated mice. (E) PAS staining demonstrating mucus production in isotype or antibody-treated groups at day 7 nV/aV. Scale bar: 250 μm. (F) Quantification of PAS+ staining as percentage of total cell detections (left) and lung area (right). (G) Eosinophil quantification after o.p. or i.p. treatment in mice at day 7 nv/aV. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0005 by 2-way ANOVA with multiple comparisons.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts